1. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
- Author
-
Maier PS and Spritzer PM
- Subjects
- Adult, Androgens blood, Anovulation drug therapy, Anovulation etiology, Anovulation genetics, Blood Pressure drug effects, Body Mass Index, Ethinyl Estradiol administration & dosage, Female, Gene Frequency, Genotype, Hirsutism blood, Hirsutism drug therapy, Hirsutism genetics, Humans, Hyperandrogenism drug therapy, Hyperandrogenism etiology, Hyperandrogenism genetics, Norpregnenes administration & dosage, Phenotype, Polycystic Ovary Syndrome complications, Spironolactone administration & dosage, Young Adult, Aromatase genetics, Contraceptives, Oral therapeutic use, Polycystic Ovary Syndrome drug therapy, Polycystic Ovary Syndrome genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Aims: To assess whether a single nucleotide polymorphism (SNP50) of the aromatase gene (CYP19) is associated with polycystic ovary syndrome (PCOS) phenotypes and to investigate the influence of this polymorphism on the response of PCOS to treatment with oral contraceptive pills (OCP)., Methods: 162 hirsute women were stratified into a classic PCOS group (hyperandrogenism, ovulatory dysfunction, c-PCOS) and an ovulatory PCOS group (hyperandrogenism, ovulatory cycles, polycystic ovaries, ov-PCOS). 51 women completed a 6-month OCP trial (20 µg ethinyl estradiol + 75 µg gestodene, 21/28 days per cycle, plus 100 mg spironolactone in 32 women with moderate to severe hirsutism). We considered the presence of the polymorphic allele A (AG+AA) in comparison to the absence of the polymorphism (GG) to express results and to perform the comparisons regarding clinical variables., Results: Mean age was 23.3 ± 6.9 years. Hirsutism score was similar in c-PCOS and ov-PCOS (15 (11-20) vs. 13 (11-20)). The differences in hormone and metabolic variables between phenotypes were independent of the presence of allele A. In the OCP trial subsample, no differences were observed between genotypes after 6 months' treatment., Conclusion: The differences between c-PCOS and ov-PCOS cannot be explained by the genetic variation at SNP50 in the CYP19 gene., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2012
- Full Text
- View/download PDF